New hope for advanced lung cancer: drug combo trial launches

NCT ID NCT05234307

Recruiting now Disease control Sponsor: Dwight Owen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug (PBF-1129) combined with an immunotherapy (nivolumab) in 30 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Participants must have already tried standard treatments including immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG NON-SMALL CELL CARCINOMA RECURRENT LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8 STAGE IVA LUNG CANCER AJCC V8 STAGE IVB LUNG CANCER AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.